PYXIS ONCOLOGY INC. - COMMON STOCK

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

27 мар 2024 07:30:00 Источник Nasdaq GlobeNewswire

Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023

21 мар 2024 07:30:00 Источник Nasdaq GlobeNewswire

Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA

13 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire

Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024

07 мар 2024 16:30:00 Источник Nasdaq GlobeNewswire

Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting

05 мар 2024 16:45:00 Источник Nasdaq GlobeNewswire

Pyxis Oncology Announces $50 Million Private Placement

27 фев 2024 08:00:00 Источник Nasdaq GlobeNewswire

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

29 дек 2023 16:30:00 Источник Nasdaq GlobeNewswire

Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer

28 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire

Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update

07 ноя 2023 16:30:00 Источник Nasdaq GlobeNewswire

Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023

27 сен 2023 09:18:58 Источник Nasdaq GlobeNewswire

Pyxis Oncology to Participate in Two Upcoming Investment Conferences

31 авг 2023 16:01:00 Источник Nasdaq GlobeNewswire

Pyxis Oncology Successfully Completes Acquisition of Apexigen

23 авг 2023 08:35:00 Источник Nasdaq GlobeNewswire

Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update

11 авг 2023 07:00:00 Источник Nasdaq GlobeNewswire

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

30 июн 2023 17:00:00 Источник Nasdaq GlobeNewswire

Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs

30 май 2023 08:30:00 Источник Nasdaq GlobeNewswire

Pyxis Oncology to Acquire Apexigen

24 май 2023 06:45:00 Источник Nasdaq GlobeNewswire

Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update

11 май 2023 07:00:01 Источник Nasdaq GlobeNewswire

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

31 мар 2023 17:00:00 Источник Nasdaq GlobeNewswire

Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update

22 мар 2023 06:45:00 Источник Nasdaq GlobeNewswire

Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors

16 мар 2023 07:30:00 Источник Nasdaq GlobeNewswire